Introduction
When ovarian cancer is detected at an early, localized stage (Stage I or II), cytoreductive surgery -currently the most effective treatment -and conventional chemotherapy can cure 70-90% of patients, compared with approximately 20% or fewer when it is diagnosed at later stages (Stages III and IV) 1 . Even aggressive high-grade, poorly differentiated or undifferentiated tumors have a much higher 5-year survival rate when diagnosed in Stage I/II rather than Stage III/IV (74% vs 27%) 2 . Clearly, early staging is critical, yet only 20-25% of ovarian cancers are diagnosed early. One option for reducing risk in high-risk women is through prophylactic bilateral salpingectomy or salpingo-oophorectomy; however, these procedures are inappropriate for normal-risk women, who represent 75-85% of ovarian cancer cases [3] [4] [5] . In light of these statistics, efforts have been made to develop effective ovarian cancer screening strategies. In this Editorial, we conduct a critical review of current ovarian cancer screening approaches, focusing on the role of ultrasound, including its strengths and weaknesses, as well as additional strategies, such as implementation of a three-stage multimodal approach, to potentially improve screening in the future.
Ovarian cancer biology
Ovarian masses are classified pathologically as benign, malignant (invasive) or of low malignant potential (borderline). Borderline tumors, which do not invade the basement membrane underlying the epithelium and have markedly atypical histology, account for approximately 15% of epithelial ovarian tumors and generally have a much better prognosis than do invasive ovarian tumors, with 10-year survival rates ranging from 85% to 98%, depending on histologic type, disease stage and patient age 6, 7 . Among invasive ovarian cancers there are two major subtypes, often classified as Type-I or Type-II tumors 8, 9 . Type-I tumors typically present in the early stages and are clinically indolent; they include low-grade serous carcinomas, low-grade endometrioid carcinomas, mucinous carcinomas, clear-cell carcinomas and malignant Brenner (transitional) tumors. Type-II tumors account for approximately 75% of epithelial ovarian cancers and include high-grade serous carcinomas, high-grade endometrioid carcinomas, undifferentiated carcinomas and malignant mixed mesodermal tumors. High-grade serous carcinoma is the most common morphology, accounting for 50-70% of invasive ovarian cancers. Most, if not all, Type-II tumors have TP53 mutations and are very aggressive, and typically they present in the late stages 10, 11 . Because Type-I tumors are generally less aggressive, they are more likely to grow slowly to a large size while remaining within the ovaries, and thus are more likely to be detected at an early stage. In contrast, aggressive Type-II ovarian tumors often metastasize before detection, with Stage-I high-grade serous ovarian cancer representing only 1% of primary ovarian cancer diagnoses using conventional methods 12, 13 . A retrospective chart review comparing the average size of primary ovarian tumors across early-stage (I/II) and late-stage (III/IV) patients further supports the theory of two distinct ovarian cancer subtypes by revealing significantly larger sizes among early-stage cases (average diameter, 10.7 cm vs 4.8 cm) 14 . Type-I tumors are believed to originate from precursor lesions in the ovary (e.g. endometriosis or borderline tumors), while Type-II tumors are thought to develop de novo from the ovarian surface epithelium, subserosal inclusion cysts or from the fimbriae of the Fallopian tubes [15] [16] [17] . Mouse models support development of high-grade serous ovarian cancer from both the Fallopian tubes and the ovaries [18] [19] [20] . Samples collected during prophylactic salpingo-oophorectomies performed on women with BRCA1 or BRCA2 germline mutations have revealed tubal involvement in an estimated 76% of early gynecologic malignancies [21] [22] [23] [24] [25] [26] . As 10-15% of invasive ovarian cancers arise in BRCA1/2-mutation carriers, at least 10% of all ovarian cancers arise from the Fallopian tubes 27, 28 . Combining this statistic with that of sporadic (non-familial) high-grade serous carcinomas that coat the ovary rather than growing from the surface and likely arise from the Fallopian tubes, which represent approximately 20% of all cases, suggests that at least 30% of ovarian cancers may originate from the Fallopian tubes [29] [30] [31] . Examination of Fallopian tube specimens has revealed high expression of p53 and clonality between serous tubal intraepithelial carcinomas and high-grade serous ovarian carcinomas [32] [33] [34] [35] . Cells in the distal region of the Fallopian tubes are likely more prone to malignant transformation due to the proinflammatory microenvironmental factors associated with ovulation, as well as the relatively large surface area of the fimbriae. Once serous tubal intraepithelial carcinoma develops, these malignant cells are believed to migrate onto the nearby ovarian surface and/or the surrounding peritoneum. Metastatic cells are transported through the peritoneal fluid and implant on the surface of the omentum or the visceral or parietal peritoneum, which provide a favorable microenvironment for growth of cancer cells [36] [37] [38] .
Background on ovarian cancer screening

Past clinical trials
Both primary ultrasound screening and multimodal strategies incorporating ultrasound have been evaluated for ovarian cancer detection in several large-scale clinical trials. The University of Kentucky Ovarian Cancer Screening Project screened with transvaginal sonography (TVS) 37 293 women annually between 1987 and 2011; to reduce false positives, measurements of the serum biomarker CA125 were also taken into account after detection of a pelvic mass 39 . The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial evaluated a non-sequential, multimodal strategy, which employed annual TVS and annual screening for single elevated values of serum CA125. The PLCO trial recruited 78 216 women between the ages of 55 and 74 to either undergo annual ovarian cancer screening (n = 39 105) or to receive conventional care (n = 39 111) 40 . Because the two screening modalities were conducted independently and not used in combination, referral to a gynecologist resulted either from abnormal TVS findings or from an elevated CA125 measurement. The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), which enrolled postmenopausal women at average risk of ovarian cancer, evaluated both a sequential, multimodal arm and a primary ultrasound arm 41 . In this trial, 101 359 women received conventional care as controls, 50 639 underwent annual ultrasound examinations, and 50 640 underwent annual CA125 measurements, which were analyzed using a risk of ovarian cancer algorithm (ROCA) 42 in which rising CA125 levels, even if within the normal range, prompted ultrasound examination. In the multimodal screening arm, rising CA125 levels prompted TVS in approximately 2% of participants each year.
Criteria for success
For a screening strategy to be considered effective, it must achieve a sufficient positive predictive value (PPV). Achieving a high PPV is important for reducing unnecessary operations and the risk of surgery-related complications in otherwise healthy women. In the UKCTOCS, 3.4% of false-positive screens (i.e. women who underwent surgery and were diagnosed with normal or benign pathology) experienced surgery-related complications (e.g. hollow viscus injury, hemorrhage, hernia, wound breakdown, infection) 43 . In the PLCO trial, a much higher surgery-related complication rate of 15% was reported across screened women who had normal or benign pathology (false-positive screens) 44 . As one might expect, in both the UKCTOCS and PLCO trials, more women underwent unnecessary operations in the screening group compared with in the usual care group 43, 44 . There is a consensus that a minimum PPV of 10% is required, such that no more than 10 operations are performed for each ovarian cancer diagnosis 45 . In addition to having sufficiently high sensitivity and specificity to achieve an adequate PPV, an effective strategy must also reduce mortality in a cost-effective manner 46 .
Trial outcomes
The University of Kentucky Ovarian Cancer Screening Project reported a PPV of 14.5% and a statistically significant stage shift, with 70% of screen-detected invasive epithelial ovarian cancers being in early Stage I or II 39 . Across all screen-detected invasive epithelial ovarian cancers, the mean ± SD 5-year survival rate was 74.8% ± 6.6% compared with 53.7% ± 2.3% for unscreened patients treated at the same facility following the same clinical practices. Because survival rates, which are subject to lead-time bias, were reported rather than mortality, these results do not, however, prove that screening reduced deaths from the disease, and the perceived survival benefit may instead be attributable to the earlier diagnosis of disease, with no impact on lifespan.
Early results from the prevalence phase of the UKCTOCS were encouraging, suggesting that sequential, multimodal screening (i.e. CA125 with ROCA followed by ultrasound) was able to detect 89.5% of all primary invasive epithelial ovarian and tubal cancers, with a specificity of 99.8% and a PPV of 35.1% (i.e. three operations for each ovarian cancer diagnosis) 41 . Furthermore, 47% of prevalent ovarian cancers detected through screening were early stage. A smaller study of 4675 women, coordinated by the MD Anderson Specialized Program of Research Excellence (SPORE) in Ovarian Cancer, which utilized the same screening approach as the multimodal arm of the UKCTOCS, reported a similar specificity of 99.9% and a PPV of 40% 47 . Mortality results from the UKCTOCS were also encouraging, with a significant reduction of 20% in the average overall mortality among patients who underwent sequential, multimodal screening (excluding prevalent cases and primary peritoneal disease); however, given the broad confidence limits around the estimate of reduced mortality, additional follow-up is needed before final conclusions can be drawn regarding the survival advantage of such screening 43 . Comparison of results from the primary ultrasound and multimodal screening arms of the UKCTOCS revealed a lower sensitivity for detecting invasive epithelial ovarian and Fallopian tube cancers diagnosed within 1 year of screening, a lower percentage of early-stage (Stage I/II) invasive ovarian, tubal and undesignated cancers, and a lower PPV for detecting invasive ovarian and tubal cancers in the ultrasound screening arm (66%, 23%, and 5% vs 87%, 38% and 23%, respectively) 43 . Furthermore, the ultrasound arm exhibited a smaller reduction in mortality of 11-12% (including prevalent cases), compared with 15-16% in the multimodal arm.
In contrast to the promising results obtained in the UKCTOCS, which suggest a high PPV, a shift to earlier stage diagnosis and a possible survival benefit, the screening strategy evaluated in the PLCO failed to improve survival or to detect an increased fraction of early-stage ovarian cancer cases 44 . Additionally, the PPV for detecting invasive ovarian cancers was much lower in the first four annual screening rounds of the PLCO than in the UKCTOCS, at 2.6% or 0.9% for women with a positive CA125 or TVS screen, respectively 48 . In retrospect, the PPV would have risen to 20% if both CA125 and TVS screens were positive, although over 80% of cases would have been missed. Possible explanations for the discrepancy between the PLCO and the UKCTOCS findings could be that a non-sequential approach was used in the PLCO (i.e. TVS and CA125 screens were conducted independently of one another). Additionally, the PLCO trial employed a fixed cut-off for CA125, whereas the UKCTOCS utilized each woman's own baseline and prompted referral for TVS even among women with CA125 levels below an arbitrary cut-off defined for the general population. Furthermore, in the UKCTOCS, women with a modest rise in CA125 and an intermediate risk of developing ovarian cancer were retested 3 months later, while, in the PLCO trial, women returned after 1 year. Another explanation for the absence of a mortality benefit in the PLCO trial could lie in the lack of a protocol for managing patients with positive screens. Management was instead left to the discretion of each patient's physician, without a clear policy for follow-up and surgical exploration 49 . Because prompt surgical intervention, optimal cytoreductive surgery and effective chemotherapy each impact survival, if physicians were unsure as to how to manage a positive screen or preferred to take a watchful waiting approach, a long lapse between an initial positive screen and surgery could have resulted, negating the expected benefit of screening and minimizing the chance of producing a stage shift.
While the inclusion of specified protocols mandating patient management following positive and negative screens was a strength of the UKCTOCS, one potential disadvantage experienced by some patients in the multimodal arm was increased time to surgical intervention, given the need for repeat testing 41 . Among women in the multimodal arm who were diagnosed with ovarian or tubal malignancies during the prevalence phase of the UKCTOCS, 21% were characterized as intermediate risk during the Level-1 screen, which called for additional follow-up testing, extending the median time to surgery to 273.9 days. A different protocol for triaging patients was followed for the ultrasound arm, in which the median time from the Level-1 scan to surgery was 81.5 days for screen-detected ovarian or tubal malignancies 41 . Although early-stage ovarian tumors are believed to double in volume every 4 months, the relevance of an extended time from detection to surgery and its effect (if any) on lifespan is unknown in this case 50 .
Benefits of including ultrasound in screening for ovarian cancer
TVS is generally accepted as the primary imaging modality for evaluation of an adnexal mass and has largely replaced transabdominal ultrasound given its detailed anatomic depiction of pelvic anatomy, superior resolution and better performance in obese patients [51] [52] [53] . TVS is an attractive screening modality because it is safe, cost-effective and well-tolerated by patients. When included as part of a multimodal ovarian cancer screening strategy based on serum biomarkers (e.g. CA125), the primary benefit of ultrasound is to reduce false positives and therefore the number of unnecessary operations. Inclusion of ultrasound can also be useful in diagnosing cases in which expression of CA125 is weak or absent, which has been shown to be the case in up to 22% of ovarian cancer tissue samples 54 .
Specificity
Some benign ovarian and gynecologic conditions (e.g. benign ovarian cysts, endometriosis, leiomyoma) cause elevated serum CA125 levels, resulting in false positives 55, 56 . Thus, the PPV of serum CA125 is insufficient to warrant its use as a stand-alone ovarian cancer screening modality. In the first four screening rounds of the PLCO, a PPV of 2.6% was achieved when using single serum CA125 levels at or above a fixed threshold of 35 U/mL, while a much higher PPV of 20% was reported when positive CA125 and TVS results were combined retrospectively 48 . As an improvement over using a fixed CA125 cut-off, applying the ROCA to CA125 measurements collected serially from over 9000 women at Royal London and St. Bartholomew's Hospitals achieved a PPV of 15% 42 . However, despite showing improvement over a threshold approach, the PPV of the ROCA approach is still inferior to that of multimodal screening (ROCA followed by TVS), which had a 23% PPV in the UKCTOCS 43 .
Physician confidence
In addition to improving the PPV of ovarian cancer screening, another potential benefit of including TVS is that physicians may be more confident and trusting of abnormal TVS results than of abnormal CA125 results: physicians in the PLCO trial were more likely to refer to surgery based on a positive ultrasound screen than on a positive serum CA125 screen. In four rounds of annual screening in the PLCO trial, the surgery rate following a positive TVS screen was 27.2%, while the surgery rate following a positive CA125 screen was 11.7%; of note, while the overall surgery rates among those with positive screens dropped after the first year, it remained higher for TVS than for CA125 in all 4 years 48 .
Sensitivity
TVS enables high-resolution imaging of the ovaries and is especially useful in distinguishing simple cysts from complex cystic masses and solid tumors, which is important given the ultrasound characteristics of histologically proven adnexal malignancies. Because the features indicative of malignancy, including cystic lesions with a large solid component, thick wall and/or septations greater than 3 mm in thickness, mural nodules and necrosis of a solid component/mass, are the same for TVS and other imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI), these modalities offer limited additional value for ovarian cancer screening. Furthermore, the spatial resolution of ultrasound generally exceeds that of CT and MRI in diagnosing small lesions. Because CT offers a comparable ability to detect malignancy, yet has a higher cost and exposes patients to ionizing radiation, it is not recommended for ovarian cancer screening 57 . Positron emission tomography (PET) with CT (PET/CT) is also not recommended for ovarian cancer screening, since it has relatively low spatial resolution, which hinders the detection of small tumors, and involves exposure to ionizing radiation. Additional challenges of using PET/CT include physiologic uptake in normal structures, such as ovarian follicles in the late follicular to early luteal phase in premenopausal women, adjacent bowel mucosa and excretion into the bladder, which may obscure small pelvic malignancies, as well as other confounding conditions that may lead to false-positive (inflammation, endometriosis, pedunculated leiomyomas) and false-negative (early adenocarcinomas, borderline/low-grade tumors) results 57 . A wide range of sensitivity and specificity (58-100% and 67-92%, respectively) has been reported for the detection, using PET or PET/CT, of ovarian malignancies in women with adnexal masses [58] [59] [60] [61] . While the sensitivity and spatial resolution of ultrasound is generally better or comparable to those of other imaging modalities, MRI has been reported to have greater accuracy and specificity in the diagnosis of malignant adnexal masses (89% and 84%, respectively, vs 64% and 40% for ultrasound) 62 . However, because of its relatively high cost and lower availability, MRI is not typically the first-line imaging modality for evaluation of adnexal masses.
Current challenges facing ultrasound in the screening setting
While imaging is the focus of this review, it is important to note that the sensitivity of a sequential, multimodal ovarian cancer screening method, such as the one evaluated in the UKCTOCS, is initially limited by the sensitivity of the first-line test (e.g. serum CA125). As such, the overall mortality benefit and cost effectiveness of screening is highly dependent upon the first-line screen 63 . That being said, second-line screening has the potential to further limit sensitivity, and the lower sensitivity reported in the ultrasound arm compared with the multimodal arm of the UKCTOCS suggests that TVS may hinder early detection. In addition to reporting lower sensitivity in the ultrasound arm, multiple cases of women with ovarian cancer who had rising serum CA125 levels but normal ultrasound screens were documented in the multimodal arm. The biology of ovarian cancer, which is believed to consist of two primary disease subtypes, poses an obstacle in that annual screening with TVS is expected to be more effective in detecting the more indolent, Type-I tumors in the early stages 39, 64 . Additionally, a significant fraction of high-grade serous ovarian cancers are believed to originate in the fimbriae of the Fallopian tubes as very small tumors before the cancer progresses to an advanced stage, yet there is little to no documented experience in imaging this anatomy.
False negatives
In the UKCTOCS, there were multiple cases in which the serum CA125 levels were rising, but TVS was normal, in women later diagnosed with ovarian cancer (i.e. false negatives). Model-based estimates indicate that the minimum tumor size necessary to secrete sufficient CA125 as to generate a positive biomarker screen (i.e. serum CA125 > 34.11 U/mL) is 116.7 mm 3 , which corresponds to a 3-mm-diameter spherical tumor 65 . Based on this estimate, it is unlikely that tumors smaller than 3 mm in diameter would be detected when using serum CA125 with a fixed cut-off of 34.11 U/mL as a first-line screen; however, ROCA (rather than a fixed cut-off) was used in the UKCTOCS, and multiple patients with serum CA125 levels below 35 U/mL were diagnosed with ovarian cancer. Thus, while the minimum tumor diameter necessary to generate a positive screen with ROCA is unknown, it may be possible to detect tumors smaller than 3 mm. Detecting very small tumors with TVS presents a challenge; of patients in the UKCTOCS diagnosed with invasive epithelial ovarian or tubal cancers that were flagged by ROCA but had CA125 levels below 35 U/mL, 41% showed no abnormality on initial TVS, possibly because their tumor volume was small, given that 49% of these patients were diagnosed at an early stage (Stage I or II) 66 . As a result of the need for repeat testing, the interval from screening to surgery was significantly longer for the low CA125 patients as compared with patients who had CA125 levels above the 35-U/mL threshold (30 vs 12 weeks, respectively) . Thus, there is a need for more sensitive imaging in those patients with positive biomarker screens; it has been suggested that improved imaging is the key to a successful ovarian cancer screening program 67 . Computer-based models estimate the median diameter of early-stage serous ovarian tumors to be < 3 mm in BRCA-positive women and, during the 4.3 years that these tumors are estimated to persist as early stage, it is believed that they are typically smaller than 9 mm in diameter for over 3.8 of those years 50 . Thus, while there may be a short window of opportunity for TVS detection of early-stage Type-II tumors which have grown to a detectable size but remain localized, this window may be missed with annual, or even semi-annual, TVS screening 68 . As a further challenge, data collected during prophylactic salpingo-oophorectomies in patients with BRCA1/2 mutations have revealed primary tumor diameters of < 10 mm in multiple late-stage (Stage III/IV) patients 21, 69 . Thus, some tumors may metastasize before ever reaching a size that is detectable by TVS. TVS also often fails to detect tumors in women with a normal ovarian volume, such as in cases of primary peritoneal cancer that involves the ovarian surface and does not cause ovarian enlargement. Several studies of women at high risk have revealed minimal to no sonographic abnormalities in patients with high-grade serous ovarian cancer, despite many being in an advanced stage of disease 70, 71 . Among the false-negative ultrasound screens in the University of Kentucky Ovarian Cancer Screening Project (i.e. women diagnosed with ovarian cancer within 12 months of a negative screen), 33% (3/9) had normal-sized ovaries with extraovarian metastases at the time of surgery and 78% were Stage III 72 . Likewise, in the prevalence phase of the UKCTOCS, all false negatives reported in the ultrasound screening arm were late stage (Stage III/IV). In the PLCO trial, 85% of screen-detected ovarian cancers with negative TVS screens were late stage at detection (Stage III/IV) and 54% of fatal screen-detected cases had negative TVS screens (not including those without TVS results) 73 . A lower 5-year survival rate in the PLCO among CA125-positive women with negative TVS screens (42% vs 67% for women with positive TVS screens) could indicate that TVS is inadequate for detecting more aggressive, fatal cancers 73 .
False positives
The overlap in sonographic features between early cancer and some benign lesions represents another limitation of ultrasound. The low PPV observed in the ultrasound screening arm compared with the multimodal arm of the UKCTOCS (5% vs 23%, respectively) illustrates the relatively high false-positive rate of ultrasound for the evaluation of adnexal masses 43 ; an even lower PPV of 0.9% based on an abnormal TVS screen was reported in the first four rounds of the PLCO trial 48 . In both the PLCO and The University of Kentucky Ovarian Cancer Screening Project, primary borderline epithelial neoplasms of the ovary were classified as false positives since they are of low malignant potential and are associated with lower mortality rates. However, these borderline tumors were considered true positives in the UKCTOCS and the majority of screen-detected borderline cases (67%) were from the ultrasound arm 43 . Of all primary ovarian cancers detected through screening, 30% were borderline in the ultrasound arm, while only 12% of those detected through multimodal screening were borderline. Furthermore, 91% of borderline tumors were detected through screening in the ultrasound arm compared with 55% in the multimodal arm. Similarly, in the initial screen of the PLCO trial, all nine non-invasive cystadenomas of low malignant potential (borderline cases) were detected through TVS 40 . In addition to detecting more borderline tumors, unpublished data from the UKCTOCS indicate that ultrasound is more sensitive for detecting Type-I vs Type-II tumors 74 . Because borderline and Type-I ovarian tumors have a much lower incidence of mortality compared with Type-II tumors, detecting an increased fraction of these cases is unlikely to have a substantial impact on mortality. Therefore, while ultrasound is capable of detecting early-stage clinically indolent lesions, such detection may reflect overdiagnosis or the detection of disease that would not, ultimately, cause mortality.
Operator dependence
A well-documented limitation of ultrasound is operator dependence 75 . While new equipment and transducers have made TVS much simpler to perform, interobserver variation still exists due to insufficient experience or to misunderstanding regarding ovarian physiological anatomy. Sonologists will likely only gain the necessary experience to improve their performance by carrying out large numbers of exams, as well as seeing the same patient repeatedly in a screening setting and comparing current to prior exams, while consistently ensuring meticulous technique.
Non-visualization
In the ultrasound arm of the UKCTOCS, 6.2% (n = 3005) of women required a repeat scan following an unsatisfactory scan in which one or both ovaries could not be visualized while also not achieving a good view of the iliac vessels 41 . Common reasons for non-visualization of the ovaries by TVS include obesity, previous gynecological surgery (hysterectomy, unilateral oophorectomy and tubal ligation), increasing age, presumably due to small atrophic ovaries, and ovaries located superiorly beyond the range of the TVS probe 76 . When the ovaries cannot be visualized with TVS, transabdominal ultrasound should be attempted, although this is unlikely to improve visualization in obese patients.
Opportunities for improvement
First-line screening
The inclusion of additional blood-based biomarkers besides CA125 (e.g. HE4 or CA72-4) could further enhance the sensitivity of first-line screening for detecting early-stage ovarian cancer [77] [78] [79] [80] . Techniques using proteomic profiles as biomarkers have also been developed for screening, but have not yet proven sufficiently sensitive or reproducible to be used clinically 81, 82 . Another potential means of improving first-line screening may come through liquid biopsies, which detect circulating tumor DNA (ctDNA) mutations, circulating tumor cells (CTCs), elevations in the overall level of cell-free DNA (cfDNA) and DNA methylation or other epigenetic biomarkers in extracted bodily fluids [83] [84] [85] [86] [87] [88] [89] [90] [91] . Liquid biopsies based on ctDNA, as compared with CTCs, may offer greater sensitivity for early detection in light of some evidence suggesting a higher yield and frequency of ctDNA in liquid biopsy samples 92 . Studies detecting ctDNA in ovarian cancer patients in the form of genetic alterations have reported a 41% (9/22) detection rate of known mutations using routine liquid Pap smear samples 93 , a 93% (28/30) detection rate of tumor-specific p53 sequence in the peritoneal wash fluid 94 , and an 80% (8/10) detection rate for tumor-specific chromosomal junctions in plasma samples 95 . Because the aforementioned studies included mainly late-stage patients, the utility of these assays for detecting early-stage disease is uncertain. Additionally, the sensitivity of such assays, which are often performed using polymerase chain reaction techniques and thus have an inherent sensitivity limit of 0.01%, may limit their use for early detection given that ctDNA represents only a fraction of total DNA in the sample 96 . While evidence of detectable concentrations of ctDNA has been reported among patients with localized disease, indicating that such liquid biopsies may prove useful for detecting early-stage cases, there is currently little or no prospective evaluation of their utility in a screening setting 92, 97 . Furthermore, there is considerable variability in the concentration of ctDNA in liquid biopsy samples across patients even at the same disease stage (e.g. ctDNA concentrations varying from < 1% to > 40% have been reported among late-stage (Stage III/IV) high-grade serous ovarian cancer patients) 95 , despite the assumption that concentration is related to tumor burden. Further study is needed to characterize this variability, as well as the relationship between disease extent and ctDNA concentration, to determine if early detection is viable. Additional limitations to the use of liquid biopsies in the screening setting are the time and cost currently required to perform such assays, as well as the potential for a lack of specificity, as in the case of screening for TP53 mutations, which have also been observed in healthy patients 98 . Because such screening may not offer complete specificity and also may not provide insight into the location of disease when a mutation common to several potential disease sites is identified (e.g. TP53), the need for additional follow-up with imaging or another method remains. However, if the sensitivity of liquid biopsies or autoantibody serum biomarkers surpasses that of traditional imaging modalities, a means of establishing specificity, as well as localizing the disease, may not exist, thus justifying the need for more sensitive second-line imaging techniques.
Second-line screening
Ultrasound technique refinement. Improving the performance and consistency of ultrasound screening is important for ensuring diagnostic accuracy as well as reducing the need for repeat scanning due to unsatisfactory exams. One means of improving screening is through the development and implementation of quality-assurance procedures, which led to higher visualization rates of the ovaries among enrolled centers over the course of the UKCTOCS; this trend was noted even among experienced sonographers (those who had performed > 1000 UKC-TOCS screens) 99 . In addition to implementing quality assurance procedures, published guidelines and standards should be followed. For instance, existing guidelines from the Society of Radiologists in Ultrasound should be utilized when evaluating asymptomatic cysts 100 . Following such guidelines would help physicians to recognize that many postmenopausal women have ovarian cysts, often exceeding 3-4 cm, which require only annual or biannual surveillance and not intervention. Furthermore, strict criteria for malignancy should be applied to complex masses, for which mural nodularity with increased blood flow is the most important factor, and hemorrhagic material should not be mistaken for septations.
To aid in the differentiation of benign vs malignant tumors, specific criteria based on ultrasound characteristics have been developed by the International Ovarian Tumor Analysis (IOTA) group to improve specificity 101 ; however, these criteria have been shown to generate a relatively higher number of inconclusive results among postmenopausal women [102] [103] [104] . A review of the ultrasound characteristics of histologically proven adnexal malignancies was conducted across a subgroup of patients from the IOTA study to classify sonographic features by disease subtype. This analysis revealed common features among borderline and Stage-I primary invasive ovarian epithelial cancers (nearly half of which (20/42) were Grade 1) relative to Stages II, III and IV primary invasive ovarian epithelial cancers, including a larger volume, a larger fraction with papillary projections, a larger fraction of multilocular cysts without solid components and a smaller proportion of purely solid tumors 105 . However, the small number of high-grade, early-stage cases documented with TVS reflects our present inability to distinguish unique sonographic characteristics among this disease subtype. The identification of common features in later-stage tumors, such as the appearance of a complex (cystic and solid) mass, which typically corresponds to ovarian cancer beyond Stage II, will not lead to earlier detection but may help to reduce the number of false positives.
While screening is typically performed on a postmenopausal patient population, annual surveillance may also be performed on premenopausal women at high risk for ovarian cancer. Additionally, some women who are labeled clinically as postmenopausal have cyclically-changing ovarian cysts and would be described more accurately as perimenopausal. In premenopausal and perimenopausal women, false positives are commonly due to misdiagnosis of physiologic cysts (e.g. corpus luteum or hemorrhagic follicular cysts) as potentially invasive cancers. In these benign cysts, hemorrhage and mural irregularity, as well as proliferation of blood vessels at the margins, is often mistaken for the complex nodularity and neovascularity of early cancer. In such cases, the impression of possible malignancy leads to further diagnostic work-up and/or surgical intervention in patients without ovarian cancer (i.e. false positives). For this reason, ultrasound examinations of high-risk premenopausal women should be performed in the first 10 days of a new menstrual cycle, to avoid the corpus luteum.
When a questionable lesion arises, a follow-up ultrasound examination should be performed 6-8 weeks after the original scan rather than diagnosing possible malignancy. This has the benefit not only of resolving definitively the indeterminate lesion and compensating for prior ultrasound exams of suboptimal technique, but also of avoiding false-positive diagnoses made by operators who are relatively inexperienced in gynecologic ultrasound. To further reduce false positives and negatives, a radiologist, gynecologist or other recognized expert should scan the patient, ensuring optimal technique. Such strategies will result in more accurate interpretation of examinations, reduce interobserver variation, and likely improve the overall performance of ultrasound imaging in the screening setting.
Doppler ultrasound. An investigational ultrasound technique is the examination of ovarian blood flow by Doppler ultrasound. Retrospective examination of ultrasound studies has resulted in reports of early-stage ovarian cancers accompanied by the presence of abnormal central ovarian blood flow, distinct from the expected hilar or normal peripheral flow 106, 107 . Patient studies have also revealed such features (i.e. central blood flow, as well as low resistance and pulsatility indices) to be associated with ovarian malignancies, although not in the setting of ovarian cancer screening [108] [109] [110] [111] [112] [113] [114] [115] [116] .
Microbubble enhancement. Microbubble contrastenhanced TVS also can be used to assess increased blood flow in an unexpected clinical setting, such as a postmenopausal ovary, and has shown promise for differentiating malignant from benign adnexal masses [117] [118] [119] [120] [121] . Although microbubble enhancement holds promise for improving specificity, it may not improve detection of early-stage disease. In the case of tumors localized to the Fallopian tubes, anatomical demonstration of the tubes by conventional ultrasound is necessary or microbubble examination will be challenging.
Integration with photoacoustic imaging. An emerging technology that can be integrated with ultrasound is photoacoustic imaging, which allows for high-resolution detection of angiogenesis, and thus has the potential to detect active neovascularization in early-stage ovarian tumors 122, 123 . Shortcomings of this approach include a limited tissue penetration depth of approximately 5 cm and a decline in spatial resolution with increasing depth; however, these limitations may be overcome through integration with TVS 124, 125 . Promising results have been obtained through ex-vivo analysis of postmenopausal human ovaries using co-registered ultrasound and photoacoustic imaging to quantify light absorption, which is related to vascular density and distribution, resulting in accurate classification of 83% of cases (10 of 12) as normal or malignant 126 . While similar results have been reported by others, sufficient in-vivo human validation data are lacking [127] [128] [129] . The administration of gold nanorod contrast agents has been shown to enhance the photoacoustic signal, as well as visualization of tumor margins, in ovarian cancer mouse models, and could be beneficial for future human use 130 .
Third-line screening
Another possible means of improving screening would be to include an additional third-line modality in patients with negative ultrasound scans preceded by positive biomarker screens. While third-line screening modalities are likely to be more expensive than TVS, the number of patients receiving such screening would be very small (e.g. < 1% of patients in the prevalence screen of the UKCTOCS) 41 , so this would not be expected to have a substantial impact on the overall cost-effectiveness of a multimodal ovarian cancer screening program.
Conventional imaging modalities.
Given its high specificity, MRI is a useful follow-up modality for discriminating sonographically indeterminate adnexal masses, and the combination of ultrasound, MRI and fluorodeoxyglucose (FDG)-PET has been shown to further improve specificity 58, 59, [131] [132] [133] . However, because ultrasound on its own generally provides high sensitivity and spatial resolution, including additional established imaging modalities is only likely to improve specificity and PPV of screening, by better distinguishing between malignant and benign masses, and is unlikely to improve sensitivity or to allow for detection of lesions at an earlier stage, and thus unlikely to impact disease-specific mortality.
Hyperpolarized MRI. An experimental technique that may offer improved sensitivity over TVS is hyperpolarized MRI. Hyperpolarized [1- 13 C]pyruvate can be used as an imaging tracer to characterize cancer metabolism and has been reported to generate a signal in the pretumors of mouse models prior to the formation of a primary tumor 134 . Hyperpolarized 13 C MRI has shown a unique signature within the tumor of prostate cancer patients and could potentially be applied to ovarian cancer as well 135 .
Magnetic relaxometry. Another promising technology for improving sensitivity in multimodal screening is magnetorelaxometry or magnetic relaxometry (MRX) 136, 137 . MRX detects binding between targeted iron oxide nanoparticles and cancer cells or tumor vessels and has been utilized for a variety of applications, including breast cancer detection in mice, detecting minimal residual disease in leukemia patient bone-marrow biopsies, and quantifying nanoparticle accumulation in biological samples [136] [137] [138] [139] [140] [141] [142] [143] [144] . Studies indicate that 10 6 ovarian cancer cells bound to superparamagnetic iron oxide nanoparticles conjugated with anti-ovarian-cancer-associated antigens can be detected 145, 146 . The application of MRX would be to detect, though not image, small cancers of the Fallopian tube or ovary and, while the expected sensitivity is greater than that of TVS, it has not yet found clinical utility.
Conclusion
The number of unnecessary operations resulting from ovarian cancer screening has been greatly reduced by using screening protocols incorporating CA125 with ROCA followed by ultrasound, as reflected by the high PPV reported in the multimodal arm of the UKCTOCS and an analogous trial performed at MD Anderson Cancer Center 47 . Moreover, a 20% reduction in mortality was achieved in the multimodal arm of the UKCTOCS, albeit with broad confidence limits around that estimate. However, while progress towards improving ovarian cancer screening has been made, there is need for further improvement. For instance, in the UKCTOCS, multiple cases were documented in which serum CA125 levels were rising, but ultrasound screens were normal, thus delaying surgical intervention. A significant factor which could contribute to false negatives is that many aggressive ovarian cancers are believed to arise from epithelial cells on the fimbriae of the Fallopian tubes, which are not readily imaged. Moreover, because only a fraction of metastatic tumors may reach a size that is detectable sonographically before they metastasize, annual screening with ultrasound may fail to detect a large fraction of early-stage ovarian cancers.
The ability to detect ovarian carcinomas before they metastasize is critical. The results of this review suggest that an opportunity for improvement, assuming that biomarkers are sufficiently sensitive to detect early-stage cases, lies in increasing the sensitivity of the second stage of screening or in the implementation of a third-line screen, in which a third modality is employed in cases in which the first-line blood-based assay is positive and the second-line ultrasound examination is negative. Future efforts towards improving screening should focus on identifying unique features specific to aggressive, early-stage tumors, as well as improving imaging sensitivity to enable detection of tubal lesions.
